HCPLive
2014 American Thoracic Society International Conference

2014 American Thoracic Society International Conference | ATS 2014

The 2014 American Thoracic Society International Conference in San Diego "will offer the latest information on clinical, basic and translational science in pulmonary, critical care and sleep medicine."

Conference Coverages

Stroke Risk Equal for Women, Men With Sleep Apnea
Stroke Risk Equal for Women, Men With Sleep Apnea
Men and women with obstructive sleep apnea are at equally increased risk of ischemic stroke, according to research presented at the annual meeting of the American Thoracic Society, held from May 16 to 21 in San Diego.
Vitamin D3 Doesn't Benefit Symptomatic Asthma
Supplementation with vitamin D3 does not reduce the rate of first treatment failure or exacerbation in adults with persistent asthma and vitamin D deficiency, according to a study published online May 18 in the Journal of the American Medical Association. This research was published to coincide with the annual meeting of the American Thoracic Society, held from May 16 to 21 in San Diego.
AMG 157 Offers Relief for Allergen-Induced Asthma
Twelve weeks of the novel AMG 157 antibody treatment may benefit patients with poorly controlled asthma, according to a study published online May 20 in the New England Journal of Medicine. This research was published to coincide with the annual meeting of the American Thoracic Society, held from May 16 to 21 in San Diego.
Monotherapy with N-acetylcysteine No Better Than Placebo for Preserving Lung Function in Patients with Idiopathic Pulmonary Fibrosis
Study results showed treatment with N-acetylcysteine did not slow the decline in lung function, reduce acute exacerbations, or improve survival compared with placebo in patients with idiopathic pulmonary fibrosis.
Nintedanib Treatment Slows Disease Progression in Patients with Idiopathic Pulmonary Fibrosis
Results from two studies show that treatment with the novel kinase inhibitor nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF). However, only one study showed nintedanib had any effect on slowing deterioration in quality of life or reducing the risk of a first acute exacerbation compared with placebo.
Pirfenidone Improves Survival in Idiopathic Pulmonary Fibrosis
Recently published study results, when combined with results from previous clinical trials, show treatment with the antifibrotic drug pirfenidone slows disease progression and improves survival in patients with idiopathic pulmonary fibrosis (IPF). These findings, if they lead the FDA to reevaluate and approve this drug, could be a game changer for patients with IPF, a disease marked by a high mortality rate and few treatment options.
Treatment with Dual Bronchodilator Produces Significant Improvements in Lung Function in Patients with COPD
Combination treatment with a fixed dose of indacaterol and glycopyrronium bromide was associated with significant improvements in several measures of lung function and health status compared to placebo and tiotropium in treatment-naïve patients with COPD.

Most Popular

$vacMongoViewPlus$ $vAR$